Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 9/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | PDE4A | P27815 | 1/20 | 0.67 |
| ▸ | KDR | P35968 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | CCR2 | P41597 | 1/20 | 0.35 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4287153 | 1.00 | CXCR4 (1.00) | CXCR4SMN1; SMN2HIF1AMAPTPDE4A | |
| SCHEMBL22199 | 1.00 | CXCR4 (1.00) | CXCR4SMN1; SMN2HIF1AMAPTPDE4A | |
| Piperazine SCHEMBL3769649 | 1.00 | CXCR4 (1.00) | CXCR4SMN1; SMN2HIF1AMAPTPDE4A | |
| SCHEMBL33477 | 1.00 | CXCR4 (1.00) | CXCR4SMN1; SMN2HIF1AMAPTPDE4A | |
| SCHEMBL8503965 | 1.00 | CXCR4 (1.00) | CXCR4SMN1; SMN2HIF1AMAPTPDE4A | |
| SCHEMBL3998680 | 1.00 | CXCR4 (1.00) | CXCR4SMN1; SMN2HIF1AMAPTPDE4A | |
| SCHEMBL18585750 | 1.00 | CXCR4 (1.00) | CXCR4SMN1; SMN2HIF1AMAPTPDE4A | |
| SCHEMBL576838 | 1.00 | CXCR4 (1.00) | CXCR4SMN1; SMN2HIF1AMAPTPDE4A | |
| SCHEMBL9947670 | 1.00 | CXCR4 (1.00) | CXCR4SMN1; SMN2HIF1AMAPTPDE4A | |
| SCHEMBL935211 | 1.00 | CXCR4 (1.00) | CXCR4SMN1; SMN2HIF1AMAPTPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119565397-A | High-flux high-chemical-resistance composite nanofiltration membrane and preparation method and application thereof | 万华化学集团股份有限公司 | 2025-03-07 | — | — | CN | claimed |
| JP-59193824-A | — | — | None | — | — | JP | disclosed |
| JP-6219945-A | — | — | None | — | — | JP | disclosed |
| WO-2025230907-A1 | A CXCR4 ANTAGONIST, A STATS ACTIVATOR, AND/OR AN AGENT THAT INCREASES NITRIC OXIDE CONTENT FOR USE IN METHODS OF IMPROVING NERVE REGENERATION | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-11-06 | — | — | WO | disclosed |
| CN-119565397-A | High-flux high-chemical-resistance composite nanofiltration membrane and preparation method and application thereof | 万华化学集团股份有限公司 | 2025-03-07 | — | — | CN | disclosed |
| US-20240297344-A1 | NONAQUEOUS ELECTROLYTE FOR SECONDARY BATTERY AND NONAQUEOUS-ELECTROLYTE SECONDARY BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-09-05 | — | — | US | disclosed |
| US-20240285831-A1 | METHODS OF USE OF MODULATORS TO IMPROVE NERVE REGENERATION | KEEFER, Edward (US) | 2024-08-29 | — | — | US | disclosed |
| CN-115911573-A | Nonaqueous electrolyte solution for secondary battery and nonaqueous electrolyte secondary battery using same | 三菱化学株式会社 | 2023-04-04 | — | — | CN | disclosed |
| US-11616253-B2 | Nonaqueous electrolyte for secondary battery and nonaqueous-electrolyte secondary battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2023-03-28 | — | — | US | disclosed |
| US-20220278370-A1 | NONAQUEOUS ELECTROLYTE FOR SECONDARY BATTERY AND NONAQUEOUS-ELECTROLYTE SECONDARY BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2022-09-01 | — | — | US | disclosed |
| US-6365583-B1 | ADMINISTERING NITROGEN CONTAINING CYCLIC COMPOUNDS FOR THERAPY OF ENHANCING WHITE BLOOD CELL COUNT | ANORMED, INC. | 2002-04-02 | — | — | US | disclosed |
| EP-1148875-A1 | METHODS AND COMPOSITIONS TO ENHANCE WHITE BLOOD CELL COUNT | ANORMED INC. (CA) | 2001-10-31 | — | — | EP | disclosed |
| US-6204259-B1 | Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide | MONSANTO COMPANY | 2001-03-20 | — | — | US | disclosed |
| WO-2000045814-A1 | METHODS AND COMPOSITIONS TO ENHANCE WHITE BLOOD CELL COUNT | ANORMED INC. (CA) | 2000-08-10 | — | — | WO | disclosed |
| EP-0679155-B1 | MANGANESE COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE | MONSANTO CO (US) | 1997-08-20 | — | — | EP | disclosed |
| EP-0679155-A1 | MANGANESE COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE. | MONSANTO CO (US) | 1995-11-02 | — | — | EP | disclosed |
| JP-H06219945-A | IMPROVEMENT OF COMPOUND | JOHNSON MATTHEY PLC | 1994-08-09 | — | — | JP | disclosed |
| WO-1994015925-A1 | MANGANESE COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE | MONSANTO COMPANY (US) | 1994-07-21 | — | — | WO | disclosed |
| JP-S59193824-A | UROLITHOTRIPTIC AGENT | AJINOMOTO CO INC | 1984-11-02 | — | — | JP | disclosed |
| US-4337154-A | FORMED FROM A POLYALKYLENIMINE AND A NITROGEN-HETEROCYCLIC SECONDARY AMINE COMPOUND | NIPPON SHOKUBAI KAGAKU KOGYO CO., LTD. (JP) | 1982-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240285831-A1 | METHODS OF USE OF MODULATORS TO IMPROVE NERVE REGENERATION | CXCR3, CXCL12, CXCR4 | CXCR4 3/4885SMN1; SMN2 1257/4885HIF1A 1991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.